Literature DB >> 20716232

Drugs, money and society (Part II).

Tom Walley1.   

Abstract

Pharmacoeconomics started as marketing but has developed into a valuable tool in the fuller assessment of drug therapies. Its principles are now widely accepted, and many countries have government-funded agencies with responsibility for its application, most notably the National Institute for Health and Clinical Excellence in England. Many clinical pharmacologists are active in this area, and the discipline itself is part of the clinical pharmacology trainees' curriculum. Further developments will include value-based pricing and its use in cost sharing arrangements between health service and manufacturers.

Mesh:

Year:  2010        PMID: 20716232      PMCID: PMC2949904          DOI: 10.1111/j.1365-2125.2009.03569.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

Authors:  Tom Walley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Is there a need for an independent centre for pharmacoeconomics in the UK?

Authors:  T Walley; R T Edwards
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

3.  Publication bias in health economic studies.

Authors:  J A Sacristán; E Bolaños; J M Hernández; J Soto; I Galende
Journal:  Pharmacoeconomics       Date:  1997-03       Impact factor: 4.981

4.  Value based pricing for NHS drugs: an opportunity not to be missed?

Authors:  Karl Claxton; Andrew Briggs; Martin J Buxton; Anthony J Culyer; Christopher McCabe; Simon Walker; Mark J Sculpher
Journal:  BMJ       Date:  2008-02-02

5.  NICE vindicated in UK's High Court.

Authors:  Richard Horton
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

Review 6.  The decade of NICE.

Authors:  Michael D Rawlins
Journal:  Lancet       Date:  2009-04-23       Impact factor: 79.321

7.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

8.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

9.  Drugs, money and society.

Authors:  T Walley
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

10.  Pharmacoeconomics: a challenge for clinical pharmacologists.

Authors:  T Walley; P Davey
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

View more
  2 in total

Review 1.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

2.  Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Authors:  Adrian Towse
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.